CN105899684B - 从纯化溶液中去除的假病毒颗粒的定量方法及试剂盒 - Google Patents

从纯化溶液中去除的假病毒颗粒的定量方法及试剂盒 Download PDF

Info

Publication number
CN105899684B
CN105899684B CN201480049583.5A CN201480049583A CN105899684B CN 105899684 B CN105899684 B CN 105899684B CN 201480049583 A CN201480049583 A CN 201480049583A CN 105899684 B CN105899684 B CN 105899684B
Authority
CN
China
Prior art keywords
mvp
solution
virus
proteins
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480049583.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105899684A (zh
Inventor
大卫·赛特琳
阿鲁·达尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mockv Solutions LLC
Original Assignee
Mockv Solutions LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mockv Solutions LLC filed Critical Mockv Solutions LLC
Publication of CN105899684A publication Critical patent/CN105899684A/zh
Application granted granted Critical
Publication of CN105899684B publication Critical patent/CN105899684B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/015—Parvoviridae, e.g. feline panleukopenia virus, human Parvovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN201480049583.5A 2013-09-10 2014-09-09 从纯化溶液中去除的假病毒颗粒的定量方法及试剂盒 Active CN105899684B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361875729P 2013-09-10 2013-09-10
US61/875,729 2013-09-10
PCT/IB2014/064352 WO2015036917A2 (en) 2013-09-10 2014-09-09 Methods and kits for quantifying the removal of mock virus particles from a purified solution

Publications (2)

Publication Number Publication Date
CN105899684A CN105899684A (zh) 2016-08-24
CN105899684B true CN105899684B (zh) 2021-06-11

Family

ID=52625972

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480049583.5A Active CN105899684B (zh) 2013-09-10 2014-09-09 从纯化溶液中去除的假病毒颗粒的定量方法及试剂盒

Country Status (7)

Country Link
US (4) US9632087B2 (https=)
EP (1) EP3044339B1 (https=)
JP (2) JP6549126B2 (https=)
CN (1) CN105899684B (https=)
AU (3) AU2014320015B2 (https=)
DK (1) DK3044339T3 (https=)
WO (1) WO2015036917A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9632087B2 (en) 2013-09-10 2017-04-25 MockV Solutions Methods for evaluating viral clearance from a biopharmaceutical solution employing mock viral particles
EP3882627B1 (en) * 2018-11-14 2024-07-10 Nissan Chemical Corporation Container and method for storing, pretreating, and analyzing biomaterial
JP7390466B2 (ja) * 2020-02-28 2023-12-01 旭化成メディカル株式会社 ウイルスクリアランス性能の評価方法
US12203914B2 (en) 2020-11-12 2025-01-21 Sartorius Bioanalytical Instruments, Inc. Viral clearance evaluation for biological medical product preparation processes
CN118465260B (zh) * 2024-07-09 2024-10-15 浙江康佰裕生物科技有限公司 测定逆转录病毒包膜蛋白elisa方法的建立及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7966987A (en) * 1986-09-08 1988-04-07 Applied Biotechnology, Inc. Empty viral capsid vaccines
US5173399A (en) * 1988-06-10 1992-12-22 Abbott Laboratories Mouse monoclonal antibodies to hiv-1p24 and their use in diagnostic tests
IL92298A (en) * 1988-11-14 2001-04-30 Us Secretary U S Dept Of Comme Method for producing isolated empty b19 parvovirus capsids, introducing genes into cells utilizing the same, diagnostic assays for detecting parvovirus infection and an anti-parvovirus vaccine containing said capsids
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
US5814442A (en) * 1994-06-10 1998-09-29 Georgetown University Internally controlled virion nucleic acid amplification reaction for quantitation of virion and virion nucleic acid
EP1268841A4 (en) 2000-03-27 2005-03-09 Smithkline Beecham Corp DETECTING VIABLE AGENTS
EP1170367A1 (en) * 2000-06-27 2002-01-09 Bayer Ag BVDV virus-like particles
US20040002058A1 (en) * 2001-06-21 2004-01-01 Uab Research Foundation Chimeric capsid proteins and uses thereof
US7041444B2 (en) * 2003-01-14 2006-05-09 Washington University Murine calicivirus
US20050196381A1 (en) * 2003-09-09 2005-09-08 Xiaobin Lu Lentivirus vector-based approaches for generating an immune response to HIV in humans
EP1973608A1 (en) * 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2007146197A1 (en) * 2006-06-09 2007-12-21 Xing-Xiang Li Methods and reagents for virus isolation and detection
WO2008036899A2 (en) * 2006-09-22 2008-03-27 Amgen Inc. Methods for removing viral contaminants during protein purification
EP2198020B1 (en) * 2007-09-14 2016-04-13 Institut Pasteur Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
GB0803068D0 (en) * 2008-02-20 2008-03-26 Health Prot Agency Cross-linked biological indicator
MX2011004201A (es) * 2008-10-20 2011-05-24 Abbott Lab Desactivacion viral durante purificacion de anticuerpos.
BR112012025364A2 (pt) * 2010-04-07 2015-09-22 Novartis Ag método para geração de partícula semelhante a vírus de parvovírus b19
US9644187B2 (en) * 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
US9632087B2 (en) * 2013-09-10 2017-04-25 MockV Solutions Methods for evaluating viral clearance from a biopharmaceutical solution employing mock viral particles

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Holger Maerz et al..Improved removal of viruslike particles from purified monoclonal antibody IgM preparation via virus filtration.《Nature Biotechnology》.1996,第14卷第651页第3栏第1段，第652页第1栏第3段. *
Improved removal of viruslike particles from purified monoclonal antibody IgM preparation via virus filtration;Holger Maerz et al.;《Nature Biotechnology》;19960531;第14卷;第651页第3栏第1段，第652页第1栏第3段 *
Native display of complete foreign protein domains on the surface of hepatitis B virus capsids;Peter A. Kratz et al.;《Proc. Natl. Acad. Sci. USA》;19990331;第96卷;摘要，第1917页右栏第1段 *

Also Published As

Publication number Publication date
WO2015036917A2 (en) 2015-03-19
JP2016529908A (ja) 2016-09-29
AU2014320015B2 (en) 2020-10-29
AU2021200484A1 (en) 2021-02-25
AU2023229501B2 (en) 2025-04-03
JP6549126B2 (ja) 2019-07-31
US20150072339A1 (en) 2015-03-12
US9632087B2 (en) 2017-04-25
AU2023229501A1 (en) 2023-09-28
EP3044339B1 (en) 2019-05-22
EP3044339A4 (en) 2017-04-26
WO2015036917A3 (en) 2015-12-03
CN105899684A (zh) 2016-08-24
US12553894B2 (en) 2026-02-17
AU2021200484B2 (en) 2023-06-29
AU2014320015A1 (en) 2016-03-31
US10309963B2 (en) 2019-06-04
US11754565B2 (en) 2023-09-12
JP2019195333A (ja) 2019-11-14
US20240085419A1 (en) 2024-03-14
US20170192001A1 (en) 2017-07-06
US20190353656A1 (en) 2019-11-21
EP3044339A2 (en) 2016-07-20
DK3044339T3 (da) 2019-08-12

Similar Documents

Publication Publication Date Title
US12553894B2 (en) Methods and kits for quantifying the removal of mock virus particles from a purified solution
Karakus et al. MHC class II proteins mediate cross-species entry of bat influenza viruses
CN110105436B (zh) 猪圆环病毒3型抗体的elisa检测试剂盒及其制备方法与应用
Chen et al. Molecular epidemiological survey of canine parvovirus circulating in China from 2014 to 2019
CN1045603A (zh) 筛选系统
CN112961865A (zh) 一种利用基因编辑鸡生物反应器表达的重组曲妥珠单抗及应用
Bruemmer et al. Structure of an insect parvovirus (Junonia coenia Densovirus) determined by cryo-electron microscopy
Janc et al. In-depth comparison of adeno-associated virus containing fractions after CsCl ultracentrifugation gradient separation
CN117964746A (zh) 一种a型口蹄疫病毒中和抗体hy2及其制备方法与应用
CN115819563B (zh) 抗猪伪狂犬病毒gE蛋白的单克隆抗体及其应用
CN104086651A (zh) 抗HCMV Pp65蛋白单克隆抗体的制备方法及其应用
CN105572375B (zh) 水貂细小病毒性肠炎病原体抗原胶体金检测试纸条及其制备方法
CN105861530B (zh) 承载GAD65 p271-284肽段的I-Ag7果蝇细胞高表达基因序列和构建的Tetramer
CN117903300A (zh) 一种a型口蹄疫病毒中和抗体hy1及其制备方法与应用
CN112409461B (zh) 流感病毒pb1蛋白抗原表位多肽及其用途
Wendlandt et al. Getting hold of the tobamovirus particle—Why and how? Purification routes over time and a new customizable approach
Vormittag et al. Advances in bioprocessing of viral vectors and virus-like particles
CN113189331A (zh) 一种烟草青枯病菌快速免疫检测试纸条及其制备方法和应用
WO2023231149A1 (en) Recombinant orthohepevirus genotype c1 orf2 protein and preparation method therefor and use thereof
CN119039427B (zh) 一株绵羊抗蓝舌病毒的重组单个b细胞抗体
CN118638825A (zh) 一种多重鼠源rna假病毒、制备方法及其应用
CN118853595A (zh) 脱脚病病毒和小鼠腺病毒假病毒制备方法及其在分子检测中的应用
RU2564007C1 (ru) Способ получения антигена вируса лейкоза крупного рогатого скота
CN115947803A (zh) 一种用于定量检测鼠疫耶尔森菌抗体的诊断抗原
Peetermans Quality Control of Vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant